Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5066181 | 0.82 | ALPI (0.43) | MEN1KMT2AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL18344466 | 0.82 | ALPI (0.43) | MEN1KMT2AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL4064873 | 0.82 | ALPI (0.43) | MEN1KMT2AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL5065706 | 0.79 | KMT2A (0.47) | CYP2C19MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL1021850 | 0.78 | LMNA (0.44) | CYP2C19MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL16195856 | 0.78 | — | — | |
| SCHEMBL2447894 | 0.76 | SLC1A1 (0.45) | PPARGPPARAALDH1A1 | |
| SCHEMBL20646317 | 0.76 | ACE (0.38) | PPARGPPARACYP2C19ACE | |
| SCHEMBL16932215 | 0.74 | MME (0.46) | PPARGPPARAACEHTTALDH1A1 | |
| SCHEMBL16932216 | 0.74 | MME (0.46) | PPARGPPARAACEHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | PPARG 2525/4885PPARA 2941/4885CYP2C19 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.